期刊文献+

阿司匹林的临床药物研究

下载PDF
导出
摘要 阿司匹林(ASA)早期主要用于止痛、退热、抗炎及抗风湿治疗。20世纪70年代发现ASA在高危患者发生心肌梗死、缺血性脑血管病的一、二级预防中是一种有效的抗血小板药物。
作者 黄瑾
出处 《临床合理用药杂志》 2011年第6期159-160,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献11

  • 1Steering. Committee of physician's Health of research Group. Preliminary report :findings from the asipilin component of the ongoing physician's health study[J]. N Eng J Med,1988,318(6) :262-264.
  • 2Cappie, Steering committee. Arandomized, blinded, trial of clopidog rel versus asipilin in patients as risk of is chacmic events(CAPRIE) [ J]. Lancet, 1996,348 : 1329 - 1339.
  • 3许俊堂,胡大一.冠心病合并糖尿病抗血小板药物的应用[J].中华心血管病杂志,2004,32(10):955-957. 被引量:8
  • 4Mehta J, Mehta P, Burger C, et al. Platclet aggregation studies in coronary arery disease [ J ]. Atneroscle Rosis, 1978,31 : 169 - 175.
  • 5Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus:a scientific state-ment from the American Heart Association and the American Diabetes Association [ J ]. Diabetes Care,2007,30 ( 1 ) : 162 - 172.
  • 6Grundy SM, Brewer B, Cleeman JI, et al. Definition of metabolic Syndrome. Report of the National heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issue Related to Definition [J]. Circulation,2004,109 (3) :433 -438.
  • 7Sane DC, McKee SA, Malinin AI, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin [ J ]. Am J Cardio1,2002,90 (8) :893 - 895.
  • 8Zhou L, Schmaier AH. Platelet aggregation testing in platelet - rich plasma: description of procedures with the aim to develop standards in the field[J]. Am J Clin Pathol,2005 ,123 :172 - 173.
  • 9Vejar M, Fragasso G, l-Iackett K, et al. Dissociation of platelet activation and apontaneous myocardial ischemia in unstable angina [ J ]. Thromb Haemost, 1990,63 (2) : 163 - 168.
  • 10Hankey GJ, Eikelboom JW. Asipilin resistance [ J ]. BMJ, 2004,328 (7438) :477 - 479.

二级参考文献10

  • 1Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care, 2003, 26: 2181-2188.
  • 2Biondi-Zoccai GG, Abbate A, Liuzzo G, et al. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol, 2003,41: 1071-1077.
  • 3Ledru F, Ducimetière P, Battaglia S, et al. New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol, 2001, 37: 1543-1550.
  • 4Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly: The Cooperative Cardiovascular Project. Am J Cardiol, 2001, 87:272-277.
  • 5McGuire, DK, Emanuelsson H, Grangen CB, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. Eur Heart J, 2000,21:1750-1758.
  • 6Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care, 2003, 26(Suppl 1): s33-s50.
  • 7Antithrombotic Trialists′ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ,2002, 324: 71-86.
  • 8Sabatine MS, Braunwald E. Will Diabetes Save the Platelet Blockers? Circulation, 2001, 104: 2759-2761.
  • 9CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet, 1996, 348: 1329-1339.
  • 100Fujita M, Mizuno K, Ho M, et al. Sarpogrelate treatment reduces restenosis after coronary stenting. Am Heart J, 2003, 145: E16-E18.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部